In its latest 13F filing, BIP Wealth LLC disclosed a 55.4% increase in its Johnson & Johnson holding during the third quarter, acquiring an additional 3,948 shares to bring its total ownership to 11,073 shares. At quarter end, that position was valued at approximately $2,053,000, reflecting the firm’s bullish view on the healthcare conglomerate.

Several other institutional investors also adjusted their J&J positions. Evolution Wealth Management initiated a $27,000 stake in the second quarter, while Clayton Financial Group opened a $28,000 position in the third. Semmax Financial Advisors lifted its holding by 55.0%, adding 72 shares for a total valuation of $31,000. GFG Capital committed roughly $35,000 to a new position, and Signature Resources Capital Management expanded its stake by 262.9%, adding 184 shares for a $47,000 total. Collectively, institutional investors now control 69.55% of the company’s outstanding shares.

Wall Street sentiment remains positive, with Citigroup raising its price target to 250 and maintaining a Buy rating, Guggenheim lifting its target to 240 with a Buy endorsement, and Raymond James Financial boosting its target to 209 and assigning an Outperform rating. Loop Capital’s objective stands at 190, and Freedom Capital shifted from Strong Buy to Hold. Among 26 surveyed analysts, one rates the stock a Strong Buy, sixteen issue Buy calls and nine recommend Hold. The consensus price objective sits at 226.18, supporting a Moderate Buy outlook.

Johnson & Johnson reported fourth-quarter EPS of 2.46, matching consensus, on revenue of 24.56 billion, a 9.1% year-over-year increase and ahead of the 24.14 billion estimate. Return on equity reached 33.3% with a net margin of 28.5%. The company set full-year guidance at 11.430-11.630 EPS. It also declared a quarterly dividend of 1.30 per share, implying an annualized payout of 5.20 and a yield near 2.4%, with a payout ratio of 47.06%.